http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 07:01:08 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Telix+and+United+Imaging+form+theranostics+collaboration/26587236.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) and United Imaging Healthcare North America announced a memorandum of understanding to evaluate a strategic research collaboration focused on theranostics solutions in the United States.</p><p>The collaboration will combine United Imaging's scanner platforms, software, connectivity and artificial intelligence capabilities with Telix's molecular imaging portfolio and clinical protocols. The companies plan to enhance integration between imaging systems and radiopharmaceutical workflows, enable protocol-driven imaging performance, and support treatment planning and patient management.</p><p>The partnership will initially focus on TLX101-Px (Pixclara, Floretyrosine F 18) in the U.S., with potential expansion into additional markets and other Telix products subject to mutual http://www.streetinsider.com/Corporate+News/Telix+and+United+Imaging+form+theranostics+collaboration/26587236.html Tue, 02 Jun 2026 07:01:08 -0400 TLX http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Press+Releases/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html <ul type="disc"><li style="text-align:justify;"><em>Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.</em></li><li style="text-align:justify;"><em>Initial focus on TLX101-Px (Pixclara®</em><em>1</em><em>, Floretyrosine F 18) in the U.S.</em></li><li style="text-align:justify;"><em>Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.</em><br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing http://www.streetinsider.com/Globe+Newswire/Telix+and+United+Imaging+Announce+Strategic+Theranostics+Collaboration/26587171.html Tue, 02 Jun 2026 07:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/FDA/Telix+presents+prostate+cancer+trial+data+showing+acceptable+safety/26584826.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) presented data from Part 1 of its ProstACT Global Phase 3 study at the American Society of Clinical Oncology Annual Meeting. The study evaluated TLX591-Tx, a lutetium radio antibody-drug conjugate, in combination with standard-of-care therapies for metastatic castration-resistant prostate cancer.</p> <p>The trial enrolled 36 patients across three treatment cohorts combining TLX591-Tx with abiraterone, enzalutamide, or docetaxel. All patients received both planned doses of the experimental treatment. The study's primary endpoint focused on safety and tolerability.</p> <p>Most treatment-related non-blood-related side effects were Grade 1-2, including fatigue in 53% of patients, nausea in 28%, and dry mouth http://www.streetinsider.com/FDA/Telix+presents+prostate+cancer+trial+data+showing+acceptable+safety/26584826.html Mon, 01 Jun 2026 17:00:28 -0400 A.06822034 A.09642568 A.22710740 A.36051124 A.50216726 O.20026344 O.20161007 O.20371933 O.21612337 O.31276474 O.31712121 TLX http://www.streetinsider.com/FDA/Telix+presents+prostate+cancer+trial+data+showing+acceptable+safety/26584826.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) presented data from Part 1 of its ProstACT Global Phase 3 study at the American Society of Clinical Oncology Annual Meeting. The study evaluated TLX591-Tx, a lutetium radio antibody-drug conjugate, in combination with standard-of-care therapies for metastatic castration-resistant prostate cancer.</p> <p>The trial enrolled 36 patients across three treatment cohorts combining TLX591-Tx with abiraterone, enzalutamide, or docetaxel. All patients received both planned doses of the experimental treatment. The study's primary endpoint focused on safety and tolerability.</p> <p>Most treatment-related non-blood-related side effects were Grade 1-2, including fatigue in 53% of patients, nausea in 28%, and dry mouth http://www.streetinsider.com/FDA/Telix+presents+prostate+cancer+trial+data+showing+acceptable+safety/26584826.html Mon, 01 Jun 2026 17:00:28 -0400 A.06822034 A.09642568 A.22710740 A.36051124 A.50216726 O.20026344 O.20161007 O.20371933 O.21612337 O.31276474 O.31712121 TLX http://www.streetinsider.com/FDA/Telix+presents+prostate+cancer+trial+data+showing+acceptable+safety/26584826.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) presented data from Part 1 of its ProstACT Global Phase 3 study at the American Society of Clinical Oncology Annual Meeting. The study evaluated TLX591-Tx, a lutetium radio antibody-drug conjugate, in combination with standard-of-care therapies for metastatic castration-resistant prostate cancer.</p> <p>The trial enrolled 36 patients across three treatment cohorts combining TLX591-Tx with abiraterone, enzalutamide, or docetaxel. All patients received both planned doses of the experimental treatment. The study's primary endpoint focused on safety and tolerability.</p> <p>Most treatment-related non-blood-related side effects were Grade 1-2, including fatigue in 53% of patients, nausea in 28%, and dry mouth http://www.streetinsider.com/FDA/Telix+presents+prostate+cancer+trial+data+showing+acceptable+safety/26584826.html Mon, 01 Jun 2026 17:00:28 -0400 A.06822034 A.09642568 A.22710740 A.36051124 A.50216726 O.20026344 O.20161007 O.20371933 O.21612337 O.31276474 O.31712121 TLX http://www.streetinsider.com/FDA/Telix+presents+prostate+cancer+trial+data+showing+acceptable+safety/26584826.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) presented data from Part 1 of its ProstACT Global Phase 3 study at the American Society of Clinical Oncology Annual Meeting. The study evaluated TLX591-Tx, a lutetium radio antibody-drug conjugate, in combination with standard-of-care therapies for metastatic castration-resistant prostate cancer.</p> <p>The trial enrolled 36 patients across three treatment cohorts combining TLX591-Tx with abiraterone, enzalutamide, or docetaxel. All patients received both planned doses of the experimental treatment. The study's primary endpoint focused on safety and tolerability.</p> <p>Most treatment-related non-blood-related side effects were Grade 1-2, including fatigue in 53% of patients, nausea in 28%, and dry mouth http://www.streetinsider.com/FDA/Telix+presents+prostate+cancer+trial+data+showing+acceptable+safety/26584826.html Mon, 01 Jun 2026 17:00:28 -0400 A.06822034 A.09642568 A.22710740 A.36051124 A.50216726 O.20026344 O.20161007 O.20371933 O.21612337 O.31276474 O.31712121 TLX http://www.streetinsider.com/FDA/Telix+presents+prostate+cancer+trial+data+showing+acceptable+safety/26584826.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) presented data from Part 1 of its ProstACT Global Phase 3 study at the American Society of Clinical Oncology Annual Meeting. The study evaluated TLX591-Tx, a lutetium radio antibody-drug conjugate, in combination with standard-of-care therapies for metastatic castration-resistant prostate cancer.</p> <p>The trial enrolled 36 patients across three treatment cohorts combining TLX591-Tx with abiraterone, enzalutamide, or docetaxel. All patients received both planned doses of the experimental treatment. The study's primary endpoint focused on safety and tolerability.</p> <p>Most treatment-related non-blood-related side effects were Grade 1-2, including fatigue in 53% of patients, nausea in 28%, and dry mouth http://www.streetinsider.com/FDA/Telix+presents+prostate+cancer+trial+data+showing+acceptable+safety/26584826.html Mon, 01 Jun 2026 17:00:28 -0400 A.06822034 A.09642568 A.22710740 A.36051124 A.50216726 O.20026344 O.20161007 O.20371933 O.21612337 O.31276474 O.31712121 TLX http://www.streetinsider.com/FDA/Telix+presents+prostate+cancer+trial+data+showing+acceptable+safety/26584826.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) presented data from Part 1 of its ProstACT Global Phase 3 study at the American Society of Clinical Oncology Annual Meeting. The study evaluated TLX591-Tx, a lutetium radio antibody-drug conjugate, in combination with standard-of-care therapies for metastatic castration-resistant prostate cancer.</p> <p>The trial enrolled 36 patients across three treatment cohorts combining TLX591-Tx with abiraterone, enzalutamide, or docetaxel. All patients received both planned doses of the experimental treatment. The study's primary endpoint focused on safety and tolerability.</p> <p>Most treatment-related non-blood-related side effects were Grade 1-2, including fatigue in 53% of patients, nausea in 28%, and dry mouth http://www.streetinsider.com/FDA/Telix+presents+prostate+cancer+trial+data+showing+acceptable+safety/26584826.html Mon, 01 Jun 2026 17:00:28 -0400 A.06822034 A.09642568 A.22710740 A.36051124 A.50216726 O.20026344 O.20161007 O.20371933 O.21612337 O.31276474 O.31712121 TLX